Cargando…

A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France

The aim was to compare the epidemiological and economic impact of 16/18 bivalent and 6/11/16/18 quadrivalent HPV vaccination in France, considering differences in licensed outcomes, protection against non-vaccine HPV types and prevention of HPV-6/11-related diseases. The differential impact of the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bresse, Xavier, Adam, Marjorie, Largeron, Nathalie, Roze, Stephane, Marty, Remi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903902/ https://www.ncbi.nlm.nih.gov/pubmed/23563511 http://dx.doi.org/10.4161/hv.22994

Ejemplares similares

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe
por: Marty, Rémi, et al.
Publicado: (2013)

Loss of chance associated with sub-optimal HPV vaccination coverage rate in France
por: Uhart, Mathieu, et al.
Publicado: (2017)

Role of vaccination in the sustainability of healthcare systems
por: Largeron, Nathalie, et al.
Publicado: (2015)

Epidemiological and economic burden of potentially HPV-related cancers in France
por: Abramowitz, Laurent, et al.
Publicado: (2018)

Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
por: Marty, Rémi, et al.
Publicado: (2012)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
por: Sivignon, Marine, et al.
Publicado: (2020)

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2017)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend
por: Gervais, Frédéric, et al.
Publicado: (2017)

Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France
por: Riethmuller, Didier, et al.
Publicado: (2015)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries
por: Roze, Stéphane, et al.
Publicado: (2012)

Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain
por: Linertová, Renata, et al.
Publicado: (2022)

A comparative public health and budget impact analysis of pneumococcal vaccines: The French case
por: Jiang, Yiling, et al.
Publicado: (2015)

Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France
por: de Rycke, Yann, et al.
Publicado: (2020)

Human Papillomavirus (HPV) Health Savings as an Alternative Solution: HPV Vaccination Behavior in Adolescents
por: Lismidiati, Wiwin, et al.
Publicado: (2021)

Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy
por: Rossi, Paolo Giorgi, et al.
Publicado: (2009)

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
por: Bregman, Bruno, et al.
Publicado: (2020)

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
por: De La Fuente, Jesús, et al.
Publicado: (2019)

“Saving lives”: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria
por: Paul, Katharina T.
Publicado: (2016)

Effect of school-based HPV vaccine campaigns on inequalities in uptake in France: the PrevHPV trial
por: Dussault, J, et al.
Publicado: (2023)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

Determinants of geographic inequalities in HPV vaccination in the most populated region of France
por: Héquet, Delphine, et al.
Publicado: (2017)

Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France
por: Roze, Stéphane, et al.
Publicado: (2020)

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
por: Petitjean, Audrey, et al.
Publicado: (2019)

Minimally important difference in cost savings: Is it possible to identify an MID for cost savings?
por: Dooley, Mary, et al.
Publicado: (2021)

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
por: Pignata, Maud, et al.
Publicado: (2017)

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
por: Basson, Mickael, et al.
Publicado: (2017)

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany
por: Préaud, Emmanuelle, et al.
Publicado: (2015)

De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics
por: Giraud, Jean-Stephane, et al.
Publicado: (2020)

The economic value of vaccination: why prevention is wealth
por: Rémy, Vanessa, et al.
Publicado: (2015)

Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
por: Hartwig, Susanne, et al.
Publicado: (2015)

Cocirculation of 2 Genotypes of Toscana Virus, Southeastern France
por: Charrel, Remi N., et al.
Publicado: (2007)

Prevention is life- and cost-saving
por: Baussano, Iacopo, et al.
Publicado: (2020)

Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
por: Knoll, Stefanie, et al.
Publicado: (2013)

Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination
por: Bartsch, Sarah M, et al.
Publicado: (2021)

Expediting COVID-19 vaccination increases QALYs and saves costs in the USA
Publicado: (2021)

Codevelopment and evaluation of a multicomponent intervention to improve HPV vaccination in France: Aurélie Bocquier
por: Bocquier, A, et al.
Publicado: (2022)

The evaluability bias in charitable giving: Saving administration costs or saving lives?
por: Caviola, Lucius, et al.
Publicado: (2014)

2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
por: Gorphe, Philippe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n816gd8a3uqfbno0coac9qhm1g